|

Prediction of Neoadjuvant Chemotherapy Response in Pancreatic Cancer

RECRUITINGSponsored by City of Hope Medical Center
Actively Recruiting
SponsorCity of Hope Medical Center
Started2024-11-15
Est. completion2026-06-18
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT07226154

Summary

This study aims to develop and validate a predictive microRNA (miRNA) panel to assess the response to neoadjuvant chemotherapy (NACT) in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma (PDAC).

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Histologically confirmed pancreatic ductal adenocarcinoma (PDAC).
* Underwent neoadjuvant chemotherapy (FOLFIRINOX or Gemcitabine/nab-paclitaxel).
* Availability of pre-treatment plasma samples.
* Underwent curative-intent resection (R0 or R1).

Exclusion Criteria:

* Inadequate plasma samples or poor RNA quality for exosomal miRNA analysis.
* Non-adenocarcinoma histology.
* Presence of synchronous or multiple primary malignancies.
* Receipt of chemotherapy regimens other than standard FOLFIRINOX or gemcitabine plus nab-paclitaxel (GEM-NABP).
* Presence of active inflammatory or autoimmune diseases.

Conditions2

CancerPancreatic Ductal Adenocarcinoma

Locations1 site

City of Hope Medical Center
Duarte, California, 91016
Ajay Goel, PhD626-218-3452ajgoel@coh.org

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.